Deep Genomics aims to revolutionize drug development using artificial intelligence built to decode RNA biology and RNA therapeutics. Our proprietary AI platform enables us to decode the enormous complexity of RNA biology to find novel targets, mechanisms, and molecules that are not accessible through traditional methods. Founded in 2015, our multidisciplinary team includes expertise in a diverse range of disciplines including those found in a traditional drug company, as well as machine learning, statistical genetics, applied data science, deep bioinformatics, software engineering and laboratory automation. Deep Genomics is based in Toronto, Ontario and Cambridge, Massachusetts.